STRO Stock Summary and Trading Ideas (Sutro Biopharma | NASDAQ:STRO)

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma trades on the NASDAQ stock market under the symbol STRO.

As of April 19, 2024, STRO stock price declined to $3.63 with 494,925 million shares trading.

STRO has a beta of 2.26, meaning it tends to be more sensitive to market movements. STRO has a correlation of 0.07 to the broad based SPY ETF.

STRO has a market cap of $279.22 million. This is considered a Small Cap stock.

Last quarter Sutro Biopharma reported $114 million in Revenue and $.52 earnings per share. This beat revenue expectation by $102 million and exceeded earnings estimates by $1.34.

In the last 3 years, STRO stock traded as high as $23.70 and as low as $2.01.

The top ETF exchange traded funds that STRO belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

STRO has underperformed the market in the last year with a price return of -19.5% while the SPY ETF gained +21.2%. STRO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.7% and -26.2%, respectively, while the SPY returned +4.3% and -3.5%, respectively.

STRO support price is $3.51 and resistance is $4.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STRO stock will trade within this expected range on the day.